Fulcrum Therapeutics Named Finalist for the 2017 Xconomy Awards in the Patient Partnership Category

August 9, 2017

Cambridge, Mass., August 9, 2017 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced that it has been named a finalist for the 2017 Xconomy Awards in the Patient Partnership category.

“We are honored to be shortlisted for this award,” said Robert J. Gould, Ph.D., Fulcrum’s President and Chief Executive Officer. “At Fulcrum, we believe that delivering transformative medicines requires deeply understanding patient needs and challenges. We strive, above all else, to be champions for our patients, and are proud of the strong relationships we have developed with our patient community.”

The Xconomy Awards were founded to honor the people, companies, and organizations that make the Boston life sciences community one of the most vibrant innovation centers in the world. The 2017 list of Xconomy Awards Finalists can be found here. Award winners will be announced at the September 26 Xconomy Awards Gala.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third Rock Ventures in 2016 and named a “Fierce 15” company later that year. For more information, please visit http://www.fulcrumtx.com/.


Sarah Sutton
Ten Bridge Communications
[email protected]